TY - JOUR
T1 - Autoimmune disease in women
T2 - Endocrine transition and risk across the lifespan
AU - Desai, Maunil K.
AU - Brinton, Roberta Diaz
N1 - Funding Information:
Autoimmune diseases are highly debilitating diseases with no cure and only moderately satisfactory but expensive treatment that nonetheless increases patients’ vulnerability to deadly infections due to prolonged immunosuppression. Autoimmune diseases result in considerable erosion in quality of life, unemployment or underemployment and increased caregiver hours. Based on the source of information, it is estimated that 5–8% (1) to 20% (American Autoimmune Related Diseases Association; https://www.aarda.org/knowledge-base/many-americans-autoimmune-disease/; accessed on Nov. 20, 2018) of all Americans suffer from at least one autoimmune disease, of which ∼78% or three-fourths patients are female, and the rest are male (Figure 3) (296). Despite this, autoimmune diseases are rarely discussed as a women’s health issue. The incidence and prevalence rates of various autoimmune diseases are rising all over the world (297, 298). At the global level, increased incidence and prevalence of autoimmune diseases in Western and Northern countries compared to Southern and Eastern countries has led to speculation that alterations in dietary habits such as highly prevalent Western diet, increased exposure to pollution as well as a changing environment may be responsible for this region-specific rise (297). The National Institutes of Allergy and Infectious Diseases (NIAID) in 2011 estimated that the cost of treating autoimmune disease in the US is >$100 billion annually (299); this excludes indirect costs to the patient and family members incurred due to decreased quality of life and loss of productivity. In contrast, autoimmune diseases research funding from NIH was $883 million in FY 2016 and $821 million in FY 2015 (300). Recently women’s health issues have received more attention, and considering autoimmune diseases are a leading cause of death among young and middle-aged women in the United States (12), the plight of autoimmune disease patients should not go unnoticed. Increased funding for research in autoimmune diseases and exploring their link to endocrine transitions, raising awareness among healthcare providers and the general population and developing better support systems for both men and women suffering from autoimmune diseases are some ways to mitigate the toll autoimmune diseases take on our society.
Funding Information:
This work was supported by National Institute on Aging (NIA) grants P01AG026572 and R37AG053589 to RB.
Publisher Copyright:
© 2019 Desai and Brinton.
PY - 2019
Y1 - 2019
N2 - Women have a higher incidence and prevalence of autoimmune diseases than men, and 85% or more patients of multiple autoimmune diseases are female. Women undergo sweeping endocrinological changes at least twice during their lifetime, puberty and menopause, with many women undergoing an additional transition: pregnancy, which may or may not be accompanied by breastfeeding. These endocrinological transitions exert significant effects on the immune system due to interactions between the hormonal milieu, innate, and adaptive immune systems as well as pro- and anti-inflammatory cytokines, and thereby modulate the susceptibility of women to autoimmune diseases. Conversely, pre-existing autoimmune diseases themselves impact endocrine transitions. Concentration-dependent effects of estrogen on the immune system; the role of progesterone, androgens, leptin, oxytocin, and prolactin; and the interplay between Th1 and Th2 immune responses together maintain a delicate balance between host defense, immunological tolerance and autoimmunity. In this review, multiple autoimmune diseases have been analyzed in the context of each of the three endocrinological transitions in women. We provide evidence from human epidemiological data and animal studies that endocrine transitions exert profound impact on the development of autoimmune diseases in women through complex mechanisms. Greater understanding of endocrine transitions and their role in autoimmune diseases could aid in prediction, prevention, and cures of these debilitating diseases in women.
AB - Women have a higher incidence and prevalence of autoimmune diseases than men, and 85% or more patients of multiple autoimmune diseases are female. Women undergo sweeping endocrinological changes at least twice during their lifetime, puberty and menopause, with many women undergoing an additional transition: pregnancy, which may or may not be accompanied by breastfeeding. These endocrinological transitions exert significant effects on the immune system due to interactions between the hormonal milieu, innate, and adaptive immune systems as well as pro- and anti-inflammatory cytokines, and thereby modulate the susceptibility of women to autoimmune diseases. Conversely, pre-existing autoimmune diseases themselves impact endocrine transitions. Concentration-dependent effects of estrogen on the immune system; the role of progesterone, androgens, leptin, oxytocin, and prolactin; and the interplay between Th1 and Th2 immune responses together maintain a delicate balance between host defense, immunological tolerance and autoimmunity. In this review, multiple autoimmune diseases have been analyzed in the context of each of the three endocrinological transitions in women. We provide evidence from human epidemiological data and animal studies that endocrine transitions exert profound impact on the development of autoimmune diseases in women through complex mechanisms. Greater understanding of endocrine transitions and their role in autoimmune diseases could aid in prediction, prevention, and cures of these debilitating diseases in women.
KW - Autoimmne disease
KW - Gender differences
KW - Menopause
KW - Puberty
KW - Women
UR - http://www.scopus.com/inward/record.url?scp=85067653927&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067653927&partnerID=8YFLogxK
U2 - 10.3389/fendo.2019.00265
DO - 10.3389/fendo.2019.00265
M3 - Review article
AN - SCOPUS:85067653927
SN - 1664-2392
VL - 10
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
IS - APR
M1 - 265
ER -